Quick Answer
Tonix Pharmaceuticals Holding Corp. reported Operating Income Loss of -$125.70 million for the year ending 2025.
- Tonix Pharmaceuticals Holding Corp. showed an increase of +8.0% in Operating Income Loss from 2024 to 2025.
- This data is from Tonix Pharmaceuticals Holding Corp.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2010 to 2025), Tonix Pharmaceuticals Holding Corp.'s Operating Income Loss has declined by 6,417.5%.
- Historical annual values: Fiscal year 2025: -$125.70 million | Fiscal year 2024: -$136.70 million | Fiscal year 2023: -$118.38 million | Fiscal year 2022: -$112.09 million | Fiscal year 2021: -$92.31 million | Fiscal year 2020: -$50.51 million | Fiscal year 2019: -$28.83 million | Fiscal year 2018: -$26.32 million | Fiscal year 2017: -$21.29 million | Fiscal year 2016: -$38.97 million | Fiscal year 2015: -$48.16 million | Fiscal year 2014: -$27.66 million | Fiscal year 2013: -$10.89 million | Fiscal year 2012: -$6.66 million | Fiscal year 2011: -$3.38 million | Fiscal year 2010: -$1.93 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: